Literature DB >> 18482793

Neurochemical pathways involved in the protective effects of nicotine and ethanol in preventing the development of Parkinson's disease: potential targets for the development of new therapeutic agents.

Roberta J Ward1, Frédéric Lallemand, Philippe de Witte, David T Dexter.   

Abstract

In this short review, neurochemical targets are identified where nicotine, and possibly ethanol, may interact to prevent the occurrence of Parkinson's disease. These are (a) the nicotinic acetycholine receptors present in the nigrostriatal area or on the surface of microglia, (b) monoamine oxidases and (c) inducible nitric oxide synthase. If such induced changes can be verified in clinical studies, this may help in the design of new therapeutic drugs which may be of relevance to diminish the incidence and perhaps the progression of the debilitating condition of Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18482793     DOI: 10.1016/j.pneurobio.2008.03.003

Source DB:  PubMed          Journal:  Prog Neurobiol        ISSN: 0301-0082            Impact factor:   11.685


  13 in total

Review 1.  Mysterious alpha6-containing nAChRs: function, pharmacology, and pathophysiology.

Authors:  Ke-chun Yang; Guo-zhang Jin; Jie Wu
Journal:  Acta Pharmacol Sin       Date:  2009-06       Impact factor: 6.150

2.  Nicotine reduces established levodopa-induced dyskinesias in a monkey model of Parkinson's disease.

Authors:  Maryka Quik; Archana Mallela; Jason Ly; Danhui Zhang
Journal:  Mov Disord       Date:  2013-07-08       Impact factor: 10.338

Review 3.  Neurotransmitter receptors and cognitive dysfunction in Alzheimer's disease and Parkinson's disease.

Authors:  Yunqi Xu; Junqiang Yan; Peng Zhou; Jiejie Li; Huimin Gao; Ying Xia; Qing Wang
Journal:  Prog Neurobiol       Date:  2012-02-25       Impact factor: 11.685

Review 4.  The ongoing pursuit of neuroprotective therapies in Parkinson disease.

Authors:  Dilan Athauda; Thomas Foltynie
Journal:  Nat Rev Neurol       Date:  2014-12-02       Impact factor: 42.937

Review 5.  Nicotine as a potential neuroprotective agent for Parkinson's disease.

Authors:  Maryka Quik; Xiomara A Perez; Tanuja Bordia
Journal:  Mov Disord       Date:  2012-06-12       Impact factor: 10.338

6.  α4β2 Nicotinic receptors play a role in the nAChR-mediated decline in L-dopa-induced dyskinesias in parkinsonian rats.

Authors:  Maryka Quik; Carla Campos; Tanuja Bordia; Jon-Paul Strachan; Jenny Zhang; J Michael McIntosh; Sharon Letchworth; Kristen Jordan
Journal:  Neuropharmacology       Date:  2013-04-12       Impact factor: 5.250

7.  ABT-089 and ABT-894 reduce levodopa-induced dyskinesias in a monkey model of Parkinson's disease.

Authors:  Danhui Zhang; Tanuja Bordia; Matthew McGregor; J Michael McIntosh; Michael W Decker; Maryka Quik
Journal:  Mov Disord       Date:  2014-02-11       Impact factor: 10.338

Review 8.  Treatment strategies for Parkinson's disease.

Authors:  Hong Yuan; Zhen-Wen Zhang; Li-Wu Liang; Quan Shen; Xiang-Dang Wang; Su-Mei Ren; Hong-Jie Ma; Shu-Jun Jiao; Ping Liu
Journal:  Neurosci Bull       Date:  2010-02       Impact factor: 5.203

Review 9.  Roles of the Functional Interaction between Brain Cholinergic and Dopaminergic Systems in the Pathogenesis and Treatment of Schizophrenia and Parkinson's Disease.

Authors:  Srijan Acharya; Kyeong-Man Kim
Journal:  Int J Mol Sci       Date:  2021-04-21       Impact factor: 5.923

10.  Down-regulation of ROCK2 alleviates ethanol-induced cerebral nerve injury partly by the suppression of the NF-κB signaling pathway.

Authors:  Xinguo Li; Jing Tong; Jihui Liu; Yibao Wang
Journal:  Bioengineered       Date:  2020-12       Impact factor: 3.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.